Histaminylation
Protein histaminylation refers to the post-translational modification in which histamine is covalently attached to glutamine residues via transamidation.
≈ 7 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Protein histaminylation refers to the post-translational modification in which histamine is covalently attached to glutamine residues via transamidation. Monoaminylation itself refers to the overall class of post-translational modifications involving monoamines; however, these reactions are further classified by the individual monoamine reactant they describe (i.e., dopaminylation, serotonylation, histaminylation).
Histaminylation has been reported for both histone and non-histone protein substrates, and thus represents a distinct neuroepigenetic and neuroproteomic regulatory mechanism with various implications in health and disease. Recent studies have revealed a critical role for histone histaminylation in regulating core components of the sleep-wake cycle and circadian rhythm in the brain.
Despite its discovery in 2012, research as to the direct links between protein histaminylation and disease has seldom occurred and its functions are still largely unknown. Nevertheless, protein histaminylation has been reported in a number of cells and tissues, including mast cells, histaminergic neurons of the posterior hypothalamic tuberomammillary nucleus (TMN), colorectal cancer cell lines, and stomach cancer cell lines.
The histaminylation proteome has remained largely unexplored due to a lack of efficient pan-specific antibodies targeting histaminylated glutamine.…
Protein histaminylation refers to the post-translational modification in which histamine is covalently attached to glutamine residues via transamidation. Monoaminylation itself refers to the overall class of post-translational modifications involving monoamines; however, these reactions are further classified by the individual monoamine reactant they describe (i.e., dopaminylation, serotonylation, histaminylation).
Histaminylation has been reported for both histone and non-histone protein substrates, and thus represents a distinct neuroepigenetic and neuroproteomic regulatory mechanism with various implications in health and disease. Recent studies have revealed a critical role for histone histaminylation in regulating core components of the sleep-wake cycle and circadian rhythm in the brain.
Despite its discovery in 2012, research as to the direct links between protein histaminylation and disease has seldom occurred and its functions are still largely unknown. Nevertheless, protein histaminylation has been reported in a number of cells and tissues, including mast cells, histaminergic neurons of the posterior hypothalamic tuberomammillary nucleus (TMN), colorectal cancer cell lines, and stomach cancer cell lines.
The histaminylation proteome has remained largely unexplored due to a lack of efficient pan-specific antibodies targeting histaminylated glutamine. To date, notable protein histaminylation substrates include several G proteins (Gαq, Gαo1, Cdc42), fibrinogen, and the histone proteins H2A, H2B, H3, and H4.
In early 2026, a recently developed Nτ-propargylated histamine (Nτ-PH) probe was successfully applied in chemical proteomic profiling of the histaminylation proteome in cancer cells. Herein, authors present emerging evidence suggesting that over 400 proteins possessed histaminylation sites in a colorectal cancer cell line (i.e., HCT 116 cells), and over 200 proteins were identified as targets of histaminylation in a stomach cancer cell line (i.e., AGS cells).
The advent of the Nτ-PH probe is anticipated to enable a more extensive investigation of histaminylation in 2026, and is expected to facilitate a substantial increase in studies on the functions of histaminylation in both health and disease.
Mechanism
Histaminylation is catalyzed by transglutaminase 2 (TGM2) in a calcium-dependent manner, and relies upon the intracellular bioavailability of histamine substrates. Generally, protein histaminylation occurs in the cytoplasm; however, histone histaminylation only occurs within the nucleus.
Nevertheless, the mechanism for TGM2-catalyzed histaminylation is identical for both histone and non-histone proteins alike. Structurally, Ca 2+ binds directly to TGM2 itself and not to the substrate molecule. Once Ca 2+ binds to TGM2, a 4 nm relaxation about the major axis of the protein exposes the active site to available substrates.
The active site itself is composed of a well conserved catalytic triad (Cys277–His335–Asp358) situated within a substrate binding channel, which is bordered by two conserved residues (Trp241 and Trp332) that facilitate catalysis through stabilization of the transition state. Once intracellular Ca 2+ binds to TGM2 and exposes the substrate binding channel, the glutamine residue of a substrate protein (i.e., histone H3, Cdc42) is free to enter the enzyme active site.
As a transamidation reaction, the mechanism for protein histaminylation can be summarized in two parts: an initial thioester formation, followed by isopeptide bond formation. Fig. 1 Mechanism for Protein Histaminylation Monoaminylation is a two step, Ca 2+ -dependent reaction in which TGM2 catalyzes the covalent attachment of histamine onto the glutamine residue of a substrate protein.
(A) The catalytic cysteine residue (Cys277) of TGM2 facilitates an initial acyl transfer reaction, which is ultimately followed by isopeptide bond formation (B). When intracellular Ca 2+ and histamine concentrations are sufficient, TGM2-catalyzed histaminylation of substrate proteins can occur. First, the catalytic cysteine residue (Cys277) in the TGM2 active site nucleophilically attacks the 𝛾-carboxamido group of the glutamine residue in an acyl transfer reaction (Fig. 1A), forming a thioester intermediate and releasing one molecule of ammonia (NH 3 ) as a result.
Next, the deprotonated primary amine of the histamine substrate nucleophilically attacks the 𝛾-thioester group of the intermediate, forming a stable isopeptide bond and ultimately releasing the enzyme (Fig. 1B). Monoaminylation Tissue Modification Biological Function References Histaminylation Tuberomammillary Nucleus (TMN) H3K4me3Q5his Displays diurnally rhythmic expression in brain; attenuates binding of WDR5 to H3 (Zheng et al., 2025) Histaminylation Tuberomammillary Nucleus (TMN) H3Q5his Diurnally rhythmic expression in the brain contributes to circadian gene expression and behavior (Zheng et al., 2025) H3K4me3Q5his expression dynamics seem to directly oppose patterns of H3K4 methylation previously implicated in circadian gene expression programs; however, loss of H3Q5 monoaminylation significantly disrupts normal patterns of circadian gene expression. Interestingly, based on a series of biochemical and structural assessments, H3K4me3Q5his was found to attenuate WDR5 complex binding to the tail of histone H3.
H3K4me3Q5his was also found to inhibit the H3K4 methyltransferase activities of MLL1-4 and SETD1A/B complexes, all of which require WDR5 as a co-factor. Taken together, H3K4me3Q5his represses H3K4 methylation through antagonization of WDR5; however, the exact mechanism describing these unfavorable interactions has yet to be described.
In addition to H3K4me3Q5his, H3K4me3Q5ser has also been shown to be involved in regulation of the circadian rhythm, showing similar patterns of diurnal expression within the tuberomammillary nucleus (TMN). Significant overlap between both H3K4me3Q5his and H3K4me3Q5ser expression in the TMN were reported during the active phase of the sleep-wake cycle; however, only H3K4me3Q5ser levels were found to taper towards the end of the active phase.
Loss of H3K4me3Q5ser at this stage correlated with a reduction in WDR5, the activity of which also peaks during the height of the active phase. Unsurprisingly, rhythmic patterns of H3K4me3Q5his and H3K4me3Q5ser (along with changes in WDR5 binding) correlate with diurnal gene expression programs associated with the CLOCK-BMAL1 transcription factor complex.
CLOCK-BMAL1 functions as a molecular oscillator, where it serves as the principal molecular machinery driving the mammalian circadian rhythm (or clock) and regulating 24-hour cycles of gene expression. H3K4me3Q5his expression within the TMN exhibited robust oscillations relative to H3K4me3 dynamics, peaking during active wake phases during the direct transcriptional governance of CLOCK-BMAL1.
These observations suggest a critical role for H3 monoaminylation dynamics in dictating WDR5 recruitment to CLOCK-BMAL1-target loci, to control H3K4 methylation states and modulate circadian gene expression programs.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1373742564 under CC BY-SA 4.0; modifications have been made.